CN102036653A - 可注射用缓释药物制剂及其制备方法 - Google Patents

可注射用缓释药物制剂及其制备方法 Download PDF

Info

Publication number
CN102036653A
CN102036653A CN2009801098042A CN200980109804A CN102036653A CN 102036653 A CN102036653 A CN 102036653A CN 2009801098042 A CN2009801098042 A CN 2009801098042A CN 200980109804 A CN200980109804 A CN 200980109804A CN 102036653 A CN102036653 A CN 102036653A
Authority
CN
China
Prior art keywords
slow
acid
releases
drug
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2009801098042A
Other languages
English (en)
Other versions
CN102036653B (zh
Inventor
刘克良
全东琴
梁远军
孟庆斌
王晨宏
何军林
贾启燕
李思成
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Yiping Medical Technology Dev Co ltd
Institute of Pharmacology and Toxicology of AMMS
Original Assignee
Chengdu Yiping Medical Technology Dev Co ltd
Institute of Pharmacology and Toxicology of AMMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Yiping Medical Technology Dev Co ltd, Institute of Pharmacology and Toxicology of AMMS filed Critical Chengdu Yiping Medical Technology Dev Co ltd
Priority to CN200980109804.2A priority Critical patent/CN102036653B/zh
Publication of CN102036653A publication Critical patent/CN102036653A/zh
Application granted granted Critical
Publication of CN102036653B publication Critical patent/CN102036653B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种可注射用缓释制剂及其制备方法，所述制剂包含治疗有效量的活性成分、两亲性分子、难溶于水的有机酸和/或其盐和油性溶剂，所述缓释药物制剂尤其适用于肽、蛋白质、核酸和糖类药物。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN200980109804.2A 2008-03-20 2009-03-20 可注射用缓释药物制剂及其制备方法 Expired - Fee Related CN102036653B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN200980109804.2A CN102036653B (zh) 2008-03-20 2009-03-20 可注射用缓释药物制剂及其制备方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/CN2008/000551 WO2009114959A1 (zh) 2008-03-20 2008-03-20 可注射用缓释药物制剂及其制备方法
CNPCT/CN2008/000551 2008-03-20
CNPCT/CN2008/00055.1 2008-03-20
CN200980109804.2A CN102036653B (zh) 2008-03-20 2009-03-20 可注射用缓释药物制剂及其制备方法
PCT/CN2009/070913 WO2009115053A1 (zh) 2008-03-20 2009-03-20 可注射用缓释药物制剂及其制备方法

Publications (2)

Publication Number Publication Date
CN102036653A true CN102036653A (zh) 2011-04-27
CN102036653B CN102036653B (zh) 2014-01-29

Family

ID=41090463

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980109804.2A Expired - Fee Related CN102036653B (zh) 2008-03-20 2009-03-20 可注射用缓释药物制剂及其制备方法

Country Status (3)

Country Link
US (1) US20110091420A1 (zh)
CN (1) CN102036653B (zh)
WO (2) WO2009114959A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104292305A (zh) * 2014-01-17 2015-01-21 河南科技大学 一种多肽、制备方法及其应用
CN105076199A (zh) * 2015-08-31 2015-11-25 江苏七洲绿色化工股份有限公司 一种除草组合物及其制备方法
CN107080835A (zh) * 2011-08-02 2017-08-22 Opko生物科学有限公司 长效生长激素及其生产方法
CN108883161A (zh) * 2016-01-15 2018-11-23 珠海贝海生物技术有限公司 包含卡巴他赛和人血清白蛋白的组合物和制剂

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011138802A1 (en) * 2010-05-07 2011-11-10 Sun Pharma Advanced Research Company Ltd., Injection solution
EA201391821A1 (ru) * 2011-06-09 2014-05-30 АМИЛИН ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Гелевые композиции
KR101494594B1 (ko) 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
CN103163258B (zh) * 2011-12-09 2015-09-23 山东绿叶制药有限公司 一种测定痕量曲普瑞林的方法
WO2013101749A1 (en) * 2011-12-29 2013-07-04 Latitude Pharmaceuticals, Inc. Stabilized glucagon nanoemulsions
CN102552169B (zh) * 2012-02-17 2015-07-29 深圳市健元医药科技有限公司 一种醋酸阿肽地尔缓释微球制剂及其制备方法
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP2016503771A (ja) 2012-12-21 2016-02-08 サノフイ エキセンジン−４誘導体
KR101586791B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
EP2832361A1 (en) * 2013-07-29 2015-02-04 Ipsen Pharma S.A.S. Aqueous sustained release compositions of LHRH analogs
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
EP3131532A1 (de) 2014-04-16 2017-02-22 Veyx-Pharma GmbH Veterinärpharmazeutische zusammensetzung und deren verwendung
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN107106659B (zh) 2014-10-27 2022-07-08 莱迪杜德制药公司 肠胃外胰高血糖素制剂
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CA3013459C (en) 2016-02-04 2020-12-29 ALASTIN Skincare, Inc. Topical compositions comprising tripeptide-1 and hexapeptide-12
EP3518892B1 (en) * 2016-09-29 2023-06-21 Arecor Limited Pharmaceutical formulation comprising an insulin compound
EP3661538A4 (en) 2017-08-03 2021-07-14 Alastin Skincare, Inc. COMPOSITIONS AND METHODS FOR IMPROVING LAXITY OF THE SKIN AND THE CONTOUR OF THE BODY
US11103455B2 (en) 2018-08-02 2021-08-31 ALASTIN Skincare, Inc. Liposomal compositions and methods of use
GB202004115D0 (en) * 2020-03-20 2020-05-06 Invex Therapeutics Ltd Modified release formulations and dosage regimens
CN114916557A (zh) * 2022-05-07 2022-08-19 渭南东旺农华生物科技有限公司 一种包含卵磷脂和γ-氨基丁酸的农用组合物
CN115624533B (zh) * 2022-12-22 2023-04-07 山东则正医药技术有限公司 一种硝苯地平控释片、制备方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013795A1 (en) * 1993-11-16 1995-05-26 Cortecs Limited Hydrophobic preparations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0451791A2 (de) * 1990-04-12 1991-10-16 Hoechst Aktiengesellschaft Langwirksame Liposomenpräparate von Peptidarzneistoffen und Verfahren zu ihrer Herstellung
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
JPWO2003015753A1 (ja) * 2001-08-20 2004-12-02 テルモ株式会社 リポソーム製剤
CN101129375B (zh) * 2007-07-06 2010-12-22 浙江大学 长春瑞滨固体脂质纳米粒与其冻干制剂及制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013795A1 (en) * 1993-11-16 1995-05-26 Cortecs Limited Hydrophobic preparations

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107080835A (zh) * 2011-08-02 2017-08-22 Opko生物科学有限公司 长效生长激素及其生产方法
CN104292305A (zh) * 2014-01-17 2015-01-21 河南科技大学 一种多肽、制备方法及其应用
CN104292305B (zh) * 2014-01-17 2017-06-09 河南科技大学 一种多肽、制备方法及其应用
CN105076199A (zh) * 2015-08-31 2015-11-25 江苏七洲绿色化工股份有限公司 一种除草组合物及其制备方法
CN108883161A (zh) * 2016-01-15 2018-11-23 珠海贝海生物技术有限公司 包含卡巴他赛和人血清白蛋白的组合物和制剂
CN108883161B (zh) * 2016-01-15 2023-04-04 珠海贝海生物技术有限公司 包含卡巴他赛和人血清白蛋白的组合物和制剂

Also Published As

Publication number Publication date
WO2009115053A1 (zh) 2009-09-24
WO2009114959A1 (zh) 2009-09-24
US20110091420A1 (en) 2011-04-21
CN102036653B (zh) 2014-01-29

Similar Documents

Publication Publication Date Title
CN102036653A (zh) 可注射用缓释药物制剂及其制备方法
CN106974888B (zh) 药物组合物和相关的给药方法
RU2128505C1 (ru) Фармацевтическая композиция с липидной системой
RU2198677C2 (ru) Фармацевтическая композиция для пероральной доставки физиологически активного пептидного агента и способ усиления его биодоступности
ES2283071T3 (es) Modulacion de la carga de medicamenteos en liposomas multivesiculares.
KR900001074B1 (ko) 약제학적 조성물
JP4814107B2 (ja) 水溶性薬物を含有する経口投与用ナノ粒子組成物及びその製造方法
US6432383B1 (en) Method for administering insulin
CN104000779A (zh) 促胰岛素释放肽的混悬制剂及其应用
JPH09510182A (ja) カプセル封入されたドラッグデリバリー用透明液
BR112014004967B1 (pt) Pré-concentrado lipídico de liberação sustentada e composição farmacêutica
NZ256413A (en) Medicaments which form a gel in vivo comprising a lecithin, a water-insoluble solvent and an active agent
CN104093399A (zh) 鲁棒性控释肽制剂
JP2005508938A (ja) プロミセル薬学的組成物
CN105055303A (zh) 含酸的脂质制剂
BR112019019596A2 (pt) composição para administração oral de fármaco, formulação de fármaco para administração oral, método para fabricar um fármaco, e, método de tratamento.
EP0706798B1 (en) Pharmaceutical composition containing biologically active peptide or protein
KR20170086049A (ko) 증가된 소수성을 가지는 단백질과 단백질 콘쥬게이트
CN102125517A (zh) 低浓度的囊泡型磷脂凝胶作为小分子肽类药物缓释载体的应用
BR112020013460A2 (pt) composições compreendendo nanopartículas à base de lipídeo para tratar diabetes mellitus
JP3804452B2 (ja) 肝炎治療剤
NZ270145A (en) Non-aqueous pharmaceutical formulation for oral administration comprising water-insoluble active agent, fatty acid solubilising agent, an oil and a surface active agent
JP2817883B2 (ja) 高度に完全なリポソームおよびその製剤法と用途
Hoyer et al. Noninvasive delivery systems for peptides and proteins in osteoporosis therapy: a retroperspective
CN1103601C (zh) 含生长激素的缓释组合物及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140129

Termination date: 20200320

CF01 Termination of patent right due to non-payment of annual fee